Statins and Venous Thrombosis: A Story Too Good to Be True?

article has not abstract

Vyšlo v časopise: Statins and Venous Thrombosis: A Story Too Good to Be True?. PLoS Med 9(9): e32767. doi:10.1371/journal.pmed.1001311
Kategorie: Perspective
prolekare.web.journal.doi_sk: https://doi.org/10.1371/journal.pmed.1001311

Souhrn

article has not abstract

Zdroje

1. RahimiK, BhalaN, KamphuisenP, EmbersonJ, Biere-RafiS, et al. (2012) Effect of statins on venous thromboembolic events: a meta-analysis of published and unpublished evidence from randomised controlled trials. PLoS Med 9: e1001310

doi:10.1371/journal.pmed.1001310.

2. RosendaalFR (1999) Risk factors for venous thrombotic disease. Thromb Haemost 82: 610–619.

3. NaessIA, ChristiansenSC, RomundstadP, CannegieterSC, RosendaalFR, et al. (2007) Incidence and mortality of venous thrombosis: a population-based study. J Thromb Haemost 5: 692–699.

4. BaglinT, LuddingtonR, BrownK, BaglinC (2003) Incidence of recurrent venous thromboembolism in relation to clinical and thrombophilic risk factors: prospective cohort study. Lancet 362: 523–526.

5. ChristiansenSC, CannegieterSC, KosterT, VandenbrouckeJP, RosendaalFR (2005) Thrombophilia, clinical factors, and recurrent venous thrombotic events. JAMA 293: 2352–2361.

6. United States Department of Health and Human Services (2008) The Surgeon's General call to action to prevent deep vein thrombosis and pulmonary embolism. Washington DC: United States Department of Health and Human services.

7. WysowskiDK, NourjahP, SwartzL (2007) Bleeding complications with warfarin use: a prevalent adverse effect resulting in regulatory action. Arch Intern Med 167: 1414–1419.

8. ÅstrupT (1958) The haemostatic balance. Thromb Diath Haemorrh (Stutt) 2: 347–357.

9. GradyD, WengerNK, HerringtonD, KhanS, FurbergC, et al. (2000) Postmenopausal hormone therapy increases risk for venous thromboembolic disease. Ann Intern Med 132: 689–696.

10. RayJG, MamdaniM, TsuyukiRT, AndersonDR, YeoEL, et al. (2001) Use of statins and the subsequent development of deep vein thrombosis. Arch Intern Med 161: 1405–1410.

11. RamcharanAS, van StralenKJ, SnoepJD, Mantel-TeeuwisseAK, RosendaalFR, et al. (2009) HMG-CoA reductase inhibitors, other lipid-lowering medication, antiplatelet therapy, and the risk of venous thrombosis. J Thromb Haemost 7: 514–520.

12. GlynnRJ, DanielsonE, FonsecaFA, GenestJ, GottoAMJr, et al. (2009) A randomized trial of rosuvastatin in the prevention of venous thromboembolism. N Engl J Med 360: 1851–1861.

13. ThomsenRW (2006) The lesser known effects of statins: benefits on infectious outcomes may be explained by “healthy user” effect. BMJ 333: 980–981.

14. DanaeiG, TavakkoliM, HernanMA (2012) Bias in observational studies of prevalent users: lessons for comparative effectiveness research from a meta-analysis of statins. Am J Epidemiol 175: 250–262.